PMID- 31158392
OWN - NLM
STAT- MEDLINE
DCOM- 20200629
LR  - 20200629
IS  - 1879-016X (Electronic)
IS  - 0163-7258 (Linking)
VI  - 202
DP  - 2019 Oct
TI  - Laminin-derived peptides: Applications in drug delivery systems for targeting.
PG  - 91-97
LID - S0163-7258(19)30100-7 [pii]
LID - 10.1016/j.pharmthera.2019.05.017 [doi]
AB  - Recently, the development of drug delivery systems (DDSs) for clinical 
      application of anticancer drugs and gene therapy has rapidly progressed. In 
      particular, DDS carriers used for chemotherapy and gene therapy are required to 
      selectively deliver drugs and genes to cancer cells. Both the carrier and the 
      molecule must in combination be highly selective in most cases. Possible 
      candidate targeting molecules are the laminins, major basement membrane proteins 
      that interact with various cells through their multiple constituent active 
      peptide sequences. Laminin-derived peptides bind to various cellular receptors 
      and have been used for DDSs as a targeting moiety. Here, we review the progress 
      in laminin-derived peptide-conjugated DDSs. Drug and gene carriers as well as 
      ultrasound diagnostic contrast agents utilizing laminin-derived peptides for 
      selective targeting are useful components of DDSs and play important roles in 
      cancer and in the neovasculature.
CI  - Copyright (c) 2019 Elsevier Inc. All rights reserved.
FAU - Negishi, Yoichi
AU  - Negishi Y
AD  - Department of Drug Delivery and Molecular Biopharmaceutics, School of Pharmacy, 
      Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0392, Japan.
FAU - Nomizu, Motoyoshi
AU  - Nomizu M
AD  - Department of Clinical Biochemistry, School of Pharmacy, Tokyo University of 
      Pharmacy and Life Sciences, Hachioji, Tokyo 192-0392, Japan. Electronic address: 
      nomizu@toyaku.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20190601
PL  - England
TA  - Pharmacol Ther
JT  - Pharmacology & therapeutics
JID - 7905840
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Laminin)
RN  - 0 (Peptides)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/pharmacology/therapeutic use
MH  - Drug Delivery Systems/methods
MH  - Humans
MH  - Laminin/*pharmacology/*therapeutic use
MH  - Neoplasms/drug therapy
MH  - Peptides/*pharmacology/*therapeutic use
OTO - NOTNLM
OT  - Drug delivery system
OT  - Laminin
OT  - Nanocarriers
OT  - Peptide
OT  - Targeting liposomes
EDAT- 2019/06/04 06:00
MHDA- 2020/07/01 06:00
CRDT- 2019/06/04 06:00
PHST- 2019/05/29 00:00 [received]
PHST- 2019/05/29 00:00 [accepted]
PHST- 2019/06/04 06:00 [pubmed]
PHST- 2020/07/01 06:00 [medline]
PHST- 2019/06/04 06:00 [entrez]
AID - S0163-7258(19)30100-7 [pii]
AID - 10.1016/j.pharmthera.2019.05.017 [doi]
PST - ppublish
SO  - Pharmacol Ther. 2019 Oct;202:91-97. doi: 10.1016/j.pharmthera.2019.05.017. Epub 
      2019 Jun 1.